… proteomics. Searching PubMed’s literature repository with terms “Alzheimer’s or Alzheimer”
and “Proteomics or Proteome” … in 2020, although the AD proteomics field emerged at the turn …

… disease progression and therapeutic responses. Keeping this goal in mind several studies
using quantitative proteomics platform … (MS)-based proteomics studies on AD and discuss the …

… from the Accelerating Medicine Partnership Program for Alzheimer's Disease (AMP-AD) …
in AD by integrating our metabolomic findings with additional proteomic data. (4) Identifying tau …

… patients with mild cognitive impairment with Alzheimer’s pathological changes (MCI(Aβ+)), …
without Alzheimer’s pathological changes. Our first aim was to define new CSF proteomic …

… disease progression and therapeutic responses. Keeping this goal in mind several studies
using quantitative proteomics platform … (MS)-based proteomics studies on AD and discuss the …

… from both total proteome and IMAC proteome. In the total proteome, 17% of peptides mapping
to Tau were phosphopeptides, while 74% of all Tau peptides in the IMAC proteome were …

… Alzheimer’s disease (AD) displays a long asymptomatic stage before dementia. We … 5xFAD
shows a proteomic signature similar to symptomatic AD but exhibits activation of autophagy …

… As accumulating evidence suggests that defects in glycosylation are involved in
Alzheimer's disease (AD) pathogenesis, in the present study, a comparative in-depth N-glycoproteomic …

Molecular changes in the brain of individuals afflicted with Alzheimer's disease (AD) are an
intense area of study. Little is known about the role of protein abundance and …

… Here, we characterized the proteomic landscape of … individuals using two different proteomic
technologies—tandem mass … CSF proteomics in autosomal dominant Alzheimer's disease …